Analyzing the Future of Next-Generation Antibody Therapeutics Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What key factors are powering the surge in the next-generation antibody therapeutics market right now?
The market size of next-generation antibody therapeutics has experienced swift expansion in the past few years. The growth from $6.82 billion in 2024 to a projected $7.63 billion in 2025 reflects a compound annual growth rate (CAGR) of 11.8%. Factors contributing to this growth during the historic period include the success of monoclonal antibodies, an increase in chronic disease incidence, approval of antibody-drug conjugates, and advancements in immunotherapy, gene therapy, and antibodies.
How fast Is the next-generation antibody therapeutics market expected to grow, and what’s its future value?
The market for next-generation antibody therapeutics is projected to undergo rapid expansion in the coming years, reaching a value of $11.52 billion in 2029, growing at a compound annual growth rate (CAGR) of 10.9%. This growth during the forecast period can be linked to various factors such as the development of biosimilars, bispecific antibodies, nanobodies, patient-centric strategies, immunomodulatory antibodies, and extending applications in autoimmune diseases, alongside constant manufacturing. Key trends to watch during the forecast period include advancements in antibody engineering and drug delivery systems, the application of digital technologies to antibody design, industry partnerships, and the use of real-world evidence in the development of antibodies.
Get your next-generation antibody therapeutics market report here!
What are the leading drivers of growth in the next-generation antibody therapeutics market?
The rise in the occurrence of chronic diseases is anticipated to fuel the expansion of the next-generation antibody therapeutics market. Chronic diseases are health conditions that persist for more than a year, requiring ongoing medical attention, limiting daily activities, or both. Next-generation antibody therapeutics offer a therapeutic utility for individuals suffering from chronic diseases, providing a more targeted approach, thereby enhancing the patient outcomes. For example, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, projected that by 2050, the population aged 50 years and above suffering from at least one chronic disease would escalate by 99.5%, reaching 142.66 million. Hence, the rising occurrence of chronic diseases is stimulating the growth of the next-generation antibody therapeutics market.
What are the key segments defining the next-generation antibody therapeutics market?
The next-generation antibody therapeutics market covered in this report is segmented –
1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp
Who are the key players steering the development of the next-generation antibody therapeutics market?
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.
What emerging trends are influencing the growth of the next-generation antibody therapeutics market?
In the upcoming next-generation antibody therapeutics market, technological advancements are emerging as a major trend. Key players in the market are emphasising on creating such advancements, including exclusive Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. The intention behind this is to improve protein identification and representation, which will provide targeted and more effective treatments. These advancements are intended to refine therapeutic profiles, decrease expenses, and treat complicated diseases with greater specificity. MIPSA is a technology that arranges protein molecules into organised assemblies to enhance scrutiny and quantification, augmenting precision and sensitivity in protein detection, useful for research and diagnostics. For example, Infinity Bio, Inc., an American biotech firm, released a next-generation antibody profiling platform in January 2024, which applies MIPSA technology for high-throughput, cost-efficient immune response analysis. This aims to enhance disease comprehension and customize treatment approaches.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12678
Which regions are most influential in expanding the next-generation antibody therapeutics market?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Next-Generation Data Storage Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/next-generation-data-storage-global-market-report
Antisense & RNAi Therapeutics Global Market Report 2024
Antibody Drug Conjugates Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
